NASDAQ: AMLX - Amylyx Pharmaceuticals

Yield per half year: +38.49%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Amylyx Pharmaceuticals

Extended chart Simple chart
Financial Markets by TradingView

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. -  основана в 2014 году, фармацевтическая компания на клинической стадии,  которая разрабатывает новые терапевтические средства для лечения бокового амиотрофического склероза (БАС) и других нейродегенеративных заболеваний. Их главный продукт AMX0035 — это двойной ингибитор апоптоза UPR-Bax, состоящий из фенилбутирата натрия, или PB, и TURSO. Они стремятся к коммерциализации продукта  AMX0035, который, является первым кандидатом в лекарство, демонстрирующим как функциональные преимущества, так и выживаемость в крупномасштабных клинических испытаниях.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2022-01-07
ISIN US03237H1014
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт https://amylyx.com
Цена ао 3.67
Change price per day: 0% (3.67)
Change price per week: -5.17% (3.87)
Change price per month: +3.97% (3.53)
Change price per 3 month: -10.92% (4.12)
Change price per half year: +38.49% (2.65)
Change price per year: +13.27% (3.24)
Change price per 3 year: -68.92% (11.81)
Change price per 5 year: 0% (3.67)
Change price per 10 year: 0% (3.67)
Change price per year to date: -9.38% (4.05)
All parameters

Underestimation

Title Value Grade
P/S 2.62 6
P/BV 2.3 6
P/E 20.23 7
EV/EBITDA 20.83 5
Total: 5.88

Efficiency

Title Value Grade
ROA, % 9.52 3
ROE, % 11.37 4
Total: 3

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.7 7
Total: 2.63

Debt

Title Value Grade
Debt/EBITDA 0.1062 10
Total: 9.4

Growth impulse

Title Value Grade
Yield Revenue, % 27099 10
Yield Ebitda, % -420.66 0
Yield EPS, % -334.65 0
Total: 2
More

Institutions Volume Share, %
Vanguard Group Inc 5 7.86
Blackrock Inc. 4 6.58
Goldman Sachs Group Inc 3 4.33
Millennium Management LLC 2 3.63
Morgan Stanley 2 3.04
State Street Corporation 2 3.03
Franklin Resources, Inc. 2 2.73
Boxer Capital, LLC 2 2.21
Two Sigma Investments, LP 1 2.11
Citadel Advisors Llc 1 1.96

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Neuroscience and Healthcare ETF 0.23805 19.72 0.03
iShares Micro-Cap ETF 0.04916 17.09 1.54048
Principal Healthcare Innovators ETF 0.01937 618.5 0.8416
Future Tech ETF 0.01937 426.34 0.8416
0.08270.410.81



Head Job title Payment Year of birth
Ms. Gina M. Mazzariello Chief Legal Officer & General Counsel 794.83k 1971 (54 years)
Ms. Shauna Horvath Head of Global Marketing N/A
Mr. Tom Holmes Chief Technical Operations Officer N/A
Mr. Chris Aiello Head of Canada & GM N/A
Mr. Joshua B. Cohen Co-Founder, Co-CEO & Director 1M 1992 (33 years)
Mr. Justin B. Klee Co-Founder, Co-CEO & Director 1M 1991 (34 years)
Mr. James M. Frates M.B.A. Chief Financial Officer 695.12k 1967 (58 years)
Lindsey Allen Head of Investor Relations & Communications N/A
Ms. Linda A. Arsenault Chief Human Resources Officer N/A
Dr. Camille L. Bedrosian M.D. Chief Medical Officer 1953 (72 years)

Address: United States, Cambridge. MA, 43 Thorndike Street - open in Google maps, open in Yandex maps
Website: https://amylyx.com